Jcar-017 Cd19-Specific Chimeric Antigen Receptor
Follicular Lymphoma
Explore 197 assets in Follicular Lymphoma →Floatz Rating
B61/100
Confidence
Indicative
Sponsor
Fred Hutchinson Cancer Center
Modality
Cell therapy
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
59High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07098364CT.gov ST-067 in Combination With CD19-Directed CAR T-Cell Therapy (Liso-cel) in Relapsed/Refractory Large B-Cell Lymphoma | — | Recruiting | — | — | — |
NCT06794268CT.gov A Study to Patients With Relapsed/Refractory Follicular Lymphoma Treated With Liso-cel (Lisocabtagene Maraleucel) in the Post Marketing Setting | — | Recruiting | — | — | — |
NCT06313996CT.gov A Study to Evaluate the Efficacy and Safety of Liso-cel Compared to Standard of Care in Adults With Relapsed or Refractory Follicular Lymphoma | — | Withdrawn | — | — | — |
NCT05633615CT.gov Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma | — | Recruiting | — | — | — |
NCT05621096CT.gov Low Dose Radiation as Bridging Therapy in Relapsed B-Cell Non-Hodgkin Lymphoma | — | Active Not Recruiting | — | — | — |
NCT05583149CT.gov Acalabrutinib + Liso-Cel In R/R Aggressive B-Cell Lymphomas | — | Active Not Recruiting | — | — | — |
NCT05359211CT.gov NKTR-255 in Combination With CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Large B-cell Lymphoma | — | Active Not Recruiting | — | — | — |
NCT03436771CT.gov Long-term Follow-up Study for Patients Previously Treated With a Juno CAR T-Cell Product | — | Terminated | — | — | — |
NCT03310619CT.gov A Safety and Efficacy Trial of JCAR017 Combinations in Subjects With Relapsed/Refractory B-cell Malignancies | — | Completed | — | — | — |
NCT02631044CT.gov Study Evaluating the Safety and Pharmacokinetics of JCAR017 in B-cell Non-Hodgkin Lymphoma (TRANSCEND-NHL-001) | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
65High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Follicular Lymphoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Jcar-017 Cd19-Specific Chimeric Antigen Receptor (this asset) | Fred Hutchinson Cancer Center | P3 | B · 61 |
| Cyclosporin A | Fred Hutchinson Cancer Center | P2/3 | BBB |
| Romidepsin | City of Hope Medical Center | P2 | BBB |
| Irinotecan | University of Michigan Rogel Cancer Center | P2 | BBB |
| Vincristine Sulfate | National Cancer Institute (NCI) | P3 | BBB |
| Recombinant Human Hyaluronidase | National Cancer Institute (NCI) | P3 | BBB |
| Busulfanum | Masonic Cancer Center, University of Minnesota | P2/3 | BBB |
| Cyclophosphamide | Merck Sharp & Dohme LLC | P4 | BB |
| Etoposide | David Bond, MD | P3 | BB |
+42 more in the Follicular Lymphoma cohort
Other indications for Jcar-017 Cd19-Specific Chimeric Antigen Receptor
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Diffuse Large B-Cell Lymphoma | — | P3 | BB · 66 |
| Non-Hodgkin Lymphoma | — | P3 | BB · 65 |
| Primary Mediastinal Large B-Cell Lymphoma | — | P2 | BB · 65 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Jcar-017 Cd19-Specific Chimeric Antigen Receptor in Follicular Lymphoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/jcar-017-cd19-specific-chimeric-antigen-receptor-follicular-lymphoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →